How is combination therapy with ACEI and ARB applied in patients with acute myocardial infarction?

Abstract

Activation of the renin-angiotensin system (RAS) has a profound effect on the prognosis of patients with myocardial infarction and/or heart failure with reduced ejection fraction (HFREF), as proven by the beneficial effects of angiotensin-converting enzyme inhibitors (ACEIs).1 Because angiotensin II is produced in the ACE-dependent and -independent pathways,2 the addition of AT1 receptor blockers (ARBs) to ACEIs is expected to completely block RAS activity and to improve the prognosis of patients with cardiovascular diseases.